Literature DB >> 15638872

Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study.

Beth A Mohr1, Andre T Guay, Amy B O'Donnell, John B McKinlay.   

Abstract

OBJECTIVE: There is little consensus on what androgen levels are 'normal' for healthy, ageing men. Using data from the Massachusetts Male Ageing Study (MMAS), we estimated age-specific, normal androgen levels for men aged 40-79 years while accounting for health status and behavioural factors known to influence hormone levels.
DESIGN: Prospective, observational study. PATIENTS: Community-based random sample of men aged 40-79 years: n = 1677 men studied at T1 (1987-1989), n = 1031 at T2 (1995-1997) and n = 631 at T3 (2002-2004), for a total of 3339 observations. The average number of years between the T1 and T2 interviews was 8.8 (range 7.1-10.4 years) and 6.4 (range 5.6-7.9 years) between T2 and T3. MEASUREMENTS: Serum total testosterone (T) and sex hormone-binding globulin (SHBG) were measured on nonfasting blood samples collected within 4 h of subject's awakening. Free and bio-available T were calculated from T and SHBG using the Sodergard equation. Trained interviewers administered an in-home questionnaire of health, medication and lifestyle. Participants were considered apparently healthy if all of the following were met: (i) absence of self-reported chronic disease (diabetes, heart disease, high blood pressure, cancer, ulcer); (ii) not on prescription medication believed to affect hormone levels; (iii) body mass index (BMI) not exceeding 29 kg/m2; (iv) alcohol consumption less than or equal to six drinks/day; and (v) nonsmoking.
RESULTS: Chronic disease and high BMI significantly decreased whereas smoking tended to increase total, free and bio-available T concentrations. Apparently healthy men had significantly higher median hormone concentrations at most time points than did not apparently healthy men. Due to the opposite effects of smoking and the other components of the definition, apparently healthy men were compared to nonsmoking, apparently unhealthy men. The former group had significantly higher androgen levels (Wilcoxon rank-sum P-values ranged from 0.01 to 0.0001) for all hormones at all interviews. Ninety-five percent of apparently healthy men in their 40s, 50s, 60s and 70s would be expected to have total T in the range (2.5-97.5th percentile): 8.7-31.7, 7.5-30.4, 6.8-29.8 and 5.4-28.4 nm (251-914, 216-876, 196-859, 156-818 ng/dl), respectively.
CONCLUSIONS: Age, health and lifestyle factors impact androgen levels and should be accounted for in calculations of normal reference ranges. We propose the following age-specific thresholds, below which a man is considered to have an abnormally low total T: 8.7, 7.5, 6.8 and 5.4 nm (251, 216, 196 and 156 ng/dl) for men in their 40s, 50s, 60s and 70s, respectively. These cutoffs correspond to the 2.5th percentile in our data; thus, approximately 2.5% of men aged 40-79 years would have abnormally low T levels based on hormone levels alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15638872     DOI: 10.1111/j.1365-2265.2004.02174.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  55 in total

1.  Erectile dysfunction in opioid users: lack of association with serum testosterone.

Authors:  Patricia A Cioe; Peter D Friedmann; Michael D Stein
Journal:  J Addict Dis       Date:  2010-10

Review 2.  Adverse effects of testosterone replacement therapy: an update on the evidence and controversy.

Authors:  Anthony Grech; John Breck; Joel Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2014-10

3.  An old emperor finds new clothing: rejuvenation in our time.

Authors:  David J Handelsman
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

4.  Lower urinary tract symptoms, erectile dysfunction, and hypogonadism.

Authors:  Michael P O'leary
Journal:  Rev Urol       Date:  2006

Review 5.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

6.  The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission.

Authors:  Thomas G Travison; Rebecca Shackelton; Andre B Araujo; Susan A Hall; Rachel E Williams; Richard V Clark; Amy B O'Donnell; John B McKinlay
Journal:  J Am Geriatr Soc       Date:  2008-05       Impact factor: 5.562

7.  Testosterone treatment of aged male mice improves some but not all aspects of age-associated increases in influenza severity.

Authors:  Landon G Vom Steeg; Sarah E Attreed; Barry Zirkin; Sabra L Klein
Journal:  Cell Immunol       Date:  2019-09-14       Impact factor: 4.868

8.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

9.  Estrogen, testosterone, and sequential movement in men.

Authors:  Jessica A Siegel; Laura A Young; Michelle B Neiss; Mary H Samuels; Charles E Roselli; Jeri S Janowsky
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

10.  Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells.

Authors:  J Y Chung; H Chen; A Midzak; A L Burnett; V Papadopoulos; B R Zirkin
Journal:  Endocrinology       Date:  2013-03-22       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.